23:25 on September 13, 2021, Beijing time, OTC market in the United StatesWUHAN GENERAL GP (WUHN.us)The stock fluctuated and the share price plummeted by 10.35%. As of press time, the stock was trading at US $0.672 per share, with a turnover of 1318 shares, a turnover rate of 0.005% and an amplitude of 5.84%.
Recent earnings data show that the stock achieved operating income of $2362.00, net profit of-$281603.00, earnings per share of-$0.010, gross profit of $419.00, and a price-to-earnings ratio of-87.23 times.
In terms of agency rating, there is currently no agency to make "buy, hold, sell" recommendations on the stock.
In the pharmaceutical industry in which WUHAN GENERAL GP shares are located in the US OTC market, the overall decline was 0.55 per cent. Among its related stocksCyclo Therapeutics Inc C/Wts 14ax 11max 2025 (To Pur Com)、Cumberland Pharmaceutical Co., Ltd.、Durect CorpThe increase is relatively large.Clarus Therapeutics Hldgs Inc、Endo Pharmaceutical、Denawi PharmaceuticalsIt is more active, with turnover rates of 6.74%, 6.60% and 6.50% respectively. The related stocks with larger amplitudes are Endo Pharmaceuticals, Clarus Therapeutics Hldgs Inc and Organogenesis Holdings Inc, with amplitudes of 17.56%, 13.31% and 13.24%, respectively.
About WUHAN GENERAL GP in American OTC Market: M2Bio Sciences Inc, formerly known as WUHAN GENERAL GP Group (China) Co., Ltd., is an alternative pharmaceutical company dedicated to the application of emerging technologies and clinical research and health applications of cannabinol (CBD)-based drugs in the human and pet care industries in Canada, the United States, Europe and Australia for cancer, cardiovascular disease, and mental illness. Chronic pain and other diseases. It provides medical-grade CBD products and quality patient care.
(the above content is completed by Money Call, a self-selected intelligent machine writer, and is only used as a reference for users to look at the market, not as a basis for transaction. )